B
BOLT
vs
T
Tel Aviv 355
Over the past 12 months, BOLT has underperformed Tel Aviv 355, delivering a return of -50% compared to the Tel Aviv 355's +59% growth.
Stocks Performance
BOLT vs Tel Aviv 355
Performance Gap
BOLT vs Tel Aviv 355
Performance By Year
BOLT vs Tel Aviv 355
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Biolight Life Sciences Ltd
Glance View
BioLight Life Sciences Ltd. engages in the management, research and development, investments or sale of solutions, the purpose of which is to address a real need that exists in the field of eye diseases. Its portfolio companies are IOptima Novel Glaucoma Treatment and Micromedic Technologies Ltd. The firm provides each of the subsidiaries with ongoing support, resources and expertise in science, regulation, business development, and intellectual property. IOptima Novel Glaucoma Treatment is engaged in the development, manufacturing and distribution of novel surgical treatments for glaucoma. Micromedic Technologies Ltd focuses, through its investee companies, on the development and commercialization of novel molecular biomarkers related to cancer, including early detection of disease, genetic risk and optimization of treatment modalities.